Turinabol: Pharmacology, East German Doping History, and Bloodwork Guide
Pharmacology and the East German story
Turinabol (4-chlorodehydromethyltestosterone) is a 17-alpha alkylated oral anabolic steroid that does not aromatize. It was developed specifically for East Germany’s state doping program and used systematically across an entire national athlete population for over a decade. Despite its reputation as mild, turinabol produces significant HDL suppression, genuine hepatotoxicity as a 17-aa oral, and since 2015 carries a WADA detection window exceeding 40 days due to newly identified long-term metabolites — a discovery that produced retrospective positive tests and medal stripping years after competition.
Turinabol: Three Facts the “Mild Oral” Narrative Obscures
“Mild” Is a Relative Term — HDL Suppression Is Not
Turinabol does not aromatize and produces less androgenic activity than Dianabol, which makes it mild by comparison. But the compound is 17-alpha alkylated, which means it suppresses HDL through hepatic lipase upregulation just as other oral steroids do. The HDL suppression from a standard turinabol cycle is significant and measurable. Users who treat it as a risk-free compound because it lacks estrogen-related side effects are ignoring its real cardiovascular impact.
It Was Built for Systematic State Doping — Not Bodybuilding
The East German government developed oral-turinabol specifically to enhance athletic performance across an entire national program. The doses used in that program — 10 to 35 mg per day — were calibrated for consistent, manageable gains in competitive athletes across multiple Olympic cycles. This context explains both the compound’s actual effect profile and why it was selected over more potent but detectably risky alternatives. Understanding the original design intent explains a lot about what turinabol actually does.
WADA Extended the Detection Window in 2015 to 40+ Days
For decades, turinabol’s detection window was considered to be approximately 5–6 weeks. In 2015, WADA-accredited laboratories identified a long-term metabolite — a sulfonated conjugate — that persists in urine significantly longer. The revised detection window exceeds 40 days and may extend beyond that in some individuals. Athletes who competed and passed testing using turinabol in earlier eras were subsequently disqualified when stored samples were retested. This is not a historical footnote — it changes the risk profile of the compound for anyone subject to anti-doping testing.
What This Turinabol Guide Covers
Covered in This Guide
- Structural origin — how turinabol differs from Dianabol and why the C4 chloro group eliminates aromatization
- The East German State Plan 14.25 — why and how oral-turinabol was developed for systematic athletic doping
- Hepatotoxicity as a 17-aa oral: timeline and dose context
- HDL suppression: mechanism and magnitude
- Turinabol vs Anavar — the non-aromatizing oral comparison with data
- SHBG binding and free testosterone implications
- The 2015 WADA detection window revision and what it means practically
- Bloodwork monitoring panel — 7 key markers
- 5 common errors in how turinabol is understood and used
Not Covered Here
- Specific turinabol doses or cycle structures
- Stacking recommendations
- PCT drug selection after use
- Sourcing or compound availability
- Female use of turinabol
- Anti-doping strategy or competition testing tactics
Foundation reading: For how oral 17-aa compounds differ structurally from injectables and why alkylation creates hepatotoxicity, see Injectable vs Oral Steroids. For HDL monitoring context, see Lipid Panel. For the liver enzyme monitoring framework, see Liver Markers (AST, ALT, GGT).
What Turinabol Is: Structure, the C4 Modification, and How It Differs from Dianabol
Turinabol is the common name for 4-chlorodehydromethyltestosterone — a synthetic anabolic-androgenic steroid developed in East Germany in the early 1960s by chemists at Jenapharm. Its chemical name describes its structural relationship to Dianabol (methandrostenolone) precisely: it is Dianabol with the addition of a chlorine atom at the C4 position of the steroid nucleus. This single modification has significant pharmacological consequences.
Dianabol (methandrostenolone) aromatizes — it converts to 17α-methylestradiol via the aromatase enzyme. This produces estrogen-related effects: water retention, gynecomastia risk, and estradiol elevation in bloodwork. The C4 chloro group in turinabol blocks this aromatization pathway. The chlorine atom at C4 prevents aromatase from acting on the steroid ring structure. The result is a compound with Dianabol’s basic anabolic framework but without the aromatization that makes Dianabol’s estrogenic side effects a primary management concern.
Like Dianabol, turinabol retains C17-alpha alkylation — the modification that makes it orally bioavailable by preventing first-pass hepatic metabolism. This means the hepatotoxicity shared by all 17-aa oral steroids is present in turinabol, regardless of its non-aromatizing status. The absence of estrogenic activity does not reduce liver strain. Turinabol’s 17-aa structure produces the same hepatic lipase upregulation and direct hepatic metabolic burden as other oral steroids — an important distinction from non-17-aa compounds. The compound also does not convert meaningfully via 5-alpha reduction, which reduces its androgenic potency in androgen-sensitive tissues (scalp, skin, prostate) compared to testosterone or Dianabol.
Half-Life and Dosing Window
Turinabol has a half-life of approximately 16 hours — longer than most oral anabolic steroids and notably longer than Dianabol (~3–6 hours) or Anavar (~9–10 hours). This extended half-life means that once-daily dosing produces relatively stable blood levels without the pronounced peak-and-trough pattern that characterises shorter-half-life orals. The practical monitoring implication is that mid-cycle bloodwork captures near-steady-state conditions more reliably than with compounds requiring split-dose administration to maintain stable levels.
State Plan 14.25: Why East Germany Built Turinabol for Systematic Doping
No compound in performance pharmacology has a more clearly documented institutional history than turinabol. Beginning in 1974, the East German government implemented a classified program — internally designated State Plan 14.25 — that administered oral-turinabol to the country’s competitive athletes across virtually every Olympic discipline. The program ran for approximately 15 years, through multiple Olympic cycles, and involved an estimated 10,000 or more athletes including minors. The documentation of this program, exposed after German reunification in 1990, provides a level of real-world usage data unavailable for most anabolic compounds.
The selection of turinabol for this program was not accidental. Chemists at Jenapharm designed the compound with specific properties that made it optimal for systematic administration to competitive athletes at the time. It produced measurable performance enhancement — increased strength, power output, and recovery — without the water retention and visible physical changes that would make detection by visual inspection straightforward. It had a detection window that was manageable relative to competition schedules using the analytical methods available in that era. And its androgenic profile was sufficiently restrained that it could be administered to female athletes at meaningful doses without producing virilisation rapid enough to attract attention or disqualification.
What the East German Dosing Data Reveals About the Compound
The documented doses used in State Plan 14.25 are one of the most informative data points available for any anabolic steroid. Male athletes typically received 10 to 35 mg per day of turinabol, with top-level male athletes sometimes reaching 35 mg. Female athletes received lower doses, typically 5–15 mg per day. These doses — calibrated for consistent performance enhancement across multi-year competitive careers — sit substantially below what performance users commonly apply today. The fact that meaningful athletic results were achieved at these doses in elite athletes over extended periods is a pharmacological data point: turinabol produces real effects at doses that the broader performance community tends to regard as underdosing. The implication is that the compound’s dose-response curve has a lower effective floor than users accustomed to higher-potency oral compounds typically expect.
Managed Visual Profile
No water retention meant athletes did not show the visible bloating associated with testosterone or Dianabol use. This reduced suspicion from officials and coaches outside the program, and made weight-class management more predictable.
Logistical Control
Oral administration allowed precise dose control and easy concealment within the program’s medical infrastructure. No injection equipment or cold-chain storage was required. Daily oral dosing could be administered under supervision.
Detection Window Management
Using era-appropriate analytical methods, oral-turinabol cleared faster than injectable anabolics and left less detectable metabolite signal. Dose timing around competition windows was systematically managed by the program’s physicians.
The 2015 WADA Metabolite Discovery: Why Turinabol’s Detection Window Is Not What It Was
For most of the compound’s history in performance use, turinabol’s detection window was understood to be approximately 5–6 weeks from the last dose, based on the metabolites that WADA-accredited laboratories were testing for. Athletes and coaches who used turinabol planned dose cessation around competition schedules based on this timeframe. For a period, this approach worked within the detection capabilities of the era.
In 2015, researchers at WADA-accredited laboratories identified a previously unknown long-term metabolite of turinabol — specifically a sulfonated (sulfate conjugate) metabolite that the body produces and retains in urine for substantially longer than the metabolites previously targeted in testing. The identification of this metabolite changed the detection window estimate to more than 40 days, with some data suggesting individual variation that could extend the window further. This is not a minor revision — it represents a more than doubling of the detectable period from the previously assumed 5–6 week window.
The practical consequence of this discovery was immediate and retroactive. Anti-doping authorities began retesting stored urine samples from major competitions using the new testing methodology. Athletes who had competed, passed testing, and received medals found their samples — stored in compliance with anti-doping regulations — now positive for turinabol metabolites. Multiple disqualifications and medal stripping orders followed, affecting athletes from competitions that had occurred years or decades earlier. The 2015 metabolite discovery is the reason turinabol carries a distinctly different detection risk profile than its historical reputation would suggest, and why any athlete subject to anti-doping testing must account for the revised window rather than the legacy 5–6 week estimate.
Note on detection context: This section describes WADA methodology for educational purposes only — to explain the pharmacokinetic reality of the compound’s metabolite profile. It does not constitute advice on evading anti-doping testing. MuscleScience.org does not endorse or support doping in sport.
Turinabol vs Anavar: The Non-Aromatizing Oral Comparison Users Get Wrong
The most common shortcut in oral steroid categorisation is grouping turinabol and Anavar (oxandrolone) together as “both mild, both non-aromatizing, essentially interchangeable.” This framing is inaccurate in several important respects. Both compounds share a class characteristic — no aromatization, 17-aa oral delivery — but differ meaningfully in androgenic activity, HDL suppression severity, hepatotoxicity ceiling, and detection window. Collapsing these differences into a single “mild oral” category produces incorrect risk expectations and under-monitoring.
| Parameter | Turinabol | Anavar (Oxandrolone) |
|---|---|---|
| Aromatization | None — C4 chloro group blocks aromatase | None — no aromatase substrate |
| Androgenic rating | ~6 (very low) | ~24 (low) |
| Hepatotoxicity (17-aa) | Moderate | Low-moderate — milder hepatic burden |
| HDL suppression | Moderate-high | Moderate — less severe |
| SHBG suppression | High — among strongest for any oral | High — similarly potent |
| Primary effect profile | Lean strength gains, muscle density | Strength, hardness, fat loss support |
| Water retention | Minimal | Minimal |
| WADA detection window | 40+ days (revised 2015) | ~3 weeks |
| Original medical context | State athletic doping program | Wasting conditions, burns, bone density |
| Half-life | ~16 hours | ~9–10 hours |
Androgenic ratings are relative to methyltestosterone = 100. Detection windows are estimates; individual variation applies. HDL suppression depends on dose and duration.
Where the Two Compounds Diverge Most
Two variables separate turinabol from oxandrolone in practical use. First, HDL suppression: the hepatic lipase upregulation from this compound is more aggressive than from Anavar, and the lipid impact reflects this — users who have run oxandrolone and found the result manageable should not assume the same from a comparable turinabol dose. Second, anti-doping detection risk: the 40+ day window versus Anavar’s ~3 weeks is not a minor difference for any tested athlete. For non-competitive users, the detection gap is academic — but the lipid gap is not, and it requires its own bloodwork rather than extrapolating from prior Anavar experience.
HDL Suppression on Turinabol: Mechanism, Magnitude, and Why It Is Underestimated
HDL cholesterol suppression is the primary cardiovascular risk of using this compound, and it is consistently underestimated because every other aspect of the turinabol side effect profile is genuinely mild. The mechanism is identical to all 17-alpha alkylated oral steroids: oral delivery through the liver upregulates hepatic lipase, an enzyme that catabolises HDL particles in circulation. HDL begins dropping within the first 1–2 weeks and reaches near-maximum suppression by week 3–4. Because the compound produces no estrogenic side effects, no water retention, and no androgenic symptoms at standard doses, users often feel entirely normal while their HDL is declining — which is why bloodwork is the only reliable monitoring tool, not subjective wellbeing.
In relative terms, turinabol sits in the moderate-to-high range for oral steroid HDL impact — worse than oxandrolone, substantially better than oxymetholone or stanozolol. This ranking matters for planning and monitoring. Prior Anavar bloodwork does not predict the lipid outcome of a turinabol cycle, and treating them as equivalent leads to under-monitoring a variable that is real and measurable. The full lipid framework is at Lipid Panel (HDL, LDL, Triglycerides); the connection between HDL-driven endothelial dysfunction and blood pressure risk is at Blood Pressure Before Steroids.
Relative HDL Suppression — Common Oral Steroids at Standard Doses
Relative suppression based on pharmacological and clinical data. Absolute HDL change depends on individual baseline, dose, and duration.
SHBG Suppression and the Free Testosterone Amplifier Effect
Among oral steroids, turinabol produces among the strongest SHBG suppression. SHBG binds testosterone in circulation, rendering the bound fraction biologically inactive; when SHBG drops, the free testosterone fraction — the portion available to bind androgen receptors — increases. In a stack that includes a testosterone base alongside the oral, this SHBG-lowering effect amplifies free testosterone beyond what the testosterone dose alone would produce. The practical consequence is that androgenic side effects from the testosterone component may be more pronounced than the testosterone dose in isolation would predict — a variable that SHBG measurement in mid-cycle bloodwork can directly quantify.
7 Bloodwork Markers to Monitor on a Turinabol Cycle
The monitoring framework for this compound centres on two variables — hepatotoxicity and HDL suppression — both of which are active from the first weeks rather than accumulating at the end of the cycle. A pre-cycle baseline, a mid-cycle draw at week 3–4, and a post-cycle assessment constitute the minimum standard. The mid-cycle timing is not arbitrary: turinabol’s peak hepatic enzyme elevation occurs by week 3–4, meaning a check at week 6 of a 6-week cycle captures the peak retrospectively rather than at a point where the information is actionable.
AST and ALT (Liver Enzymes)
The primary safety variable on any turinabol cycle. As a 17-aa oral, the compound elevates liver enzymes within 10–14 days, peaking around week 3–4. Mid-cycle bloodwork timed to this window — not week 6 — captures the actual hepatic peak. A 1.5–3× elevation above the upper limit of normal is expected; values above 5× warrant dose reduction or termination. Post-cycle normalisation must be confirmed before starting any subsequent oral compound. See Liver Markers (AST, ALT, GGT).
HDL Cholesterol
Moderate-to-high HDL suppression via hepatic lipase upregulation is the principal cardiovascular risk of turinabol use. Baseline HDL establishes the reference; mid-cycle HDL at week 3–4 captures near-peak suppression. Values below 30 mg/dL represent meaningful endothelial risk. Stacking with a second oral steroid compounds HDL impact from both compounds — the combined result is substantially worse than either alone. See Lipid Panel.
GGT (Gamma-Glutamyl Transferase)
GGT elevation alongside AST/ALT confirms the enzyme rise is hepatic rather than muscle-derived. During hard resistance training concurrent with any 17-aa oral, muscle-sourced AST can inflate the apparent liver signal. A GGT that tracks AST/ALT on a turinabol cycle confirms the hepatic origin and validates that the elevation reflects the compound’s actual liver impact. GGT is also slower to normalise post-cycle than ALT, making it a useful recovery marker. See Liver Markers.
Blood Pressure
The compound does not produce fluid retention-driven blood pressure elevation the way aromatizing steroids do. However, HDL suppression contributes to endothelial dysfunction and vascular resistance over a turinabol cycle. Weekly home readings throughout the cycle are more useful than a single clinic measurement — they capture the trend. Users entering with pre-existing elevated blood pressure carry amplified cardiovascular risk from the added lipid impact. See Blood Pressure Before Steroids.
SHBG and Free Testosterone
Turinabol suppresses SHBG strongly. Monitoring SHBG mid-cycle explains amplified effects — both androgenic and anabolic — that appear disproportionate to the testosterone dose in a stacked cycle. A low SHBG reading indicates a larger fraction of total testosterone is active in the free form. Post-cycle SHBG recovery alongside liver enzyme normalisation gives a composite picture of system recovery after the oral cycle ends.
Total Testosterone and LH/FSH
The compound suppresses the HPTA at any practical dose — LH and FSH will be suppressed during use. Post-cycle LH and FSH recovery confirms HPG axis reactivation. When turinabol is run as a kickstart alongside a longer injectable, the suppression window is determined by the injectable’s clearance, not by the oral’s 16-hour half-life. Post-cycle assessment should follow the injectable’s elimination timeline accordingly. See Hormonal Recovery After Steroids.
Complete Blood Count (CBC)
Modest erythropoietic stimulation occurs during a turinabol cycle — red blood cell production increases mildly, though far less than boldenone or testosterone. A pre-cycle CBC establishes baseline hematocrit. Values above 52% add thrombotic risk on top of the lipid burden already present. This variable becomes more directly relevant when the oral compound is stacked with compounds that elevate RBC count more substantially. See Blood Tests Before Steroids.
5 Mistakes in How Turinabol Is Used and Understood
- Mistake 1
Assuming the Pre-2015 Detection Window Still Applies
For decades, turinabol’s detection window was understood to be 5–6 weeks from the last dose. In 2015, WADA-accredited laboratories identified a long-term sulfate metabolite that persists in urine far longer than the metabolites previously targeted. The revised window is 40+ days, with individual variation potentially extending it further. Any athlete who plans dose cessation timing based on the old 5–6 week estimate is working from outdated data. The retrospective disqualifications of competitors who passed testing at the time — and later failed on stored samples retested with the new methodology — are the clearest evidence that the historical window cannot be relied upon for this compound.
- Mistake 2
Treating Turinabol as Equivalent to Anavar for Lipid Risk
Both compounds are non-aromatizing 17-aa orals, and this shared classification leads users to assume equivalent cardiovascular risk. The pharmacological data does not support this. Turinabol produces more pronounced HDL suppression than oxandrolone at comparable doses — the hepatic lipase upregulation is measurably more aggressive. Users who have run Anavar and found the lipid impact manageable should not import that experience to a cycle using this compound. A dedicated lipid baseline and mid-cycle draw are required regardless of prior Anavar bloodwork. See Lipid Panel.
- Mistake 3
Overdosing Relative to What the Evidence Supports
The East German state program — the most systematically documented real-world use of turinabol — produced meaningful athletic enhancement at 10–35 mg per day in elite competitors across multiple Olympic cycles. The performance community typically runs the compound at 40–80 mg or higher, applying dose logic from more potent orals. Above 40–50 mg per day, the incremental anabolic return does not keep pace with the additional hepatic and lipid burden the higher dose produces. More milligrams means more liver enzyme elevation, more HDL suppression, and more HPTA suppression — with diminishing anabolic return per unit dose above the effective ceiling. The historical East German data is a meaningful corrective to the assumption that bodybuilding-level doses are required for the compound to work.
- Mistake 4
Running Turinabol Concurrently with Another 17-aa Oral
Combining two oral 17-alpha alkylated steroids simultaneously — for example, this compound alongside Winstrol or Dianabol — compounds hepatic lipase upregulation from both and doubles the direct liver metabolic burden. Neither compound cancels out the other’s hepatotoxicity. The combined HDL suppression is substantially more severe than either alone. Sequential oral use — turinabol as a kickstart in weeks 1–6, another compound later in the cycle — is a structurally different risk profile from running both concurrently. Users who choose concurrent stacking are producing a cardiovascular and hepatic impact significantly beyond what either compound contributes individually. See Injectable vs Oral Steroids.
- Mistake 5
Skipping Mid-Cycle Bloodwork Because the Compound “Feels Fine”
Hepatotoxicity from 17-aa oral steroids is largely asymptomatic in the mild-to-moderate range. Elevated AST/ALT and suppressed HDL on a turinabol cycle produce no reliable subjective signal. A user can feel entirely normal — training well, recovering normally, no obvious physical change — while liver enzymes are 3× above baseline and HDL has dropped to clinically low levels. The absence of symptoms is not evidence of absence of effect. The mid-cycle blood draw at week 3–4 captures the compound’s hepatic and lipid peak at the point where it is still actionable — the dose can be reduced, the cycle shortened, or the user continues informed rather than blind. See Blood Tests Before Steroids.
Published Research Referenced in This Guide
- Schiffer L, Barnard L, Baranowski ES, et al. Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes. Drug Metab Dispos. 2016;44(2):227–237. pubmed.ncbi.nlm.nih.gov/26658226
- Liu J, Piper T, Wolber G, et al. Combined chemical and biotechnological production of 20βOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT). Drug Test Anal. 2018. pubmed.ncbi.nlm.nih.gov/29544993
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521. pubmed.ncbi.nlm.nih.gov/18500378
- Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–554. pubmed.ncbi.nlm.nih.gov/15248788
- Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis. 1987;7(3):230–236. pubmed.ncbi.nlm.nih.gov/3317860
What Turinabol Requires: Accurate Risk Framing, Updated Detection Knowledge, and Timed Monitoring
The “mild oral” framing that attaches to this compound is accurate in a narrow sense — no aromatization, manageable androgenic activity, and a hepatotoxicity ceiling well below oxymetholone. In every other relevant dimension, turinabol demands the same monitoring discipline as any 17-alpha alkylated oral steroid. HDL suppression begins within the first two weeks and is more pronounced than Anavar at equivalent doses. Liver enzyme elevation peaks by week 3–4 — a mid-cycle draw at that point is the operative safety check, not a week-6 retrospective. The detection window was extended to 40+ days in 2015, retroactively disqualifying athletes who believed they had cleared the threshold under the old estimate.
The East German state doping program that shaped the compound’s development remains the most systematically documented real-world evidence base for any anabolic steroid in history. Doses of 10–35 mg per day produced meaningful results in elite athletes over multiple Olympic cycles — far below what the performance community commonly applies to a turinabol cycle today. This is pharmacological evidence that the effective dose floor is lower than assumed, and that escalating beyond the productive dose range adds hepatic and lipid risk without proportional anabolic return. Used with an accurate understanding of its actual properties, the compound is predictable. Used within the myths surrounding it, it is not.
- Liver Markers (AST, ALT, GGT) — hepatotoxicity monitoring framework and how to interpret enzyme elevation on a 17-aa oral cycle
- Lipid Panel (HDL, LDL, Triglycerides) — HDL suppression mechanism and why the turinabol lipid impact exceeds Anavar’s at comparable doses
- Anavar (Oxandrolone) — the non-aromatizing oral most commonly compared to turinabol and where the two compounds genuinely differ
- Dianabol (Methandrostenolone) — the structural parent and how the C4 chloro modification changes the pharmacological profile
- Injectable vs Oral Steroids — why 17-alpha alkylation creates hepatotoxicity and how oral compound risk differs from injectables
- Blood Pressure Before Steroids — cardiovascular baseline and the connection between HDL suppression and vascular risk over a cycle
- Blood Tests Before Steroids — the full pre-cycle panel and why mid-cycle timing for oral steroids differs from injectable monitoring
- Hormonal Recovery After Steroids — HPTA suppression and recovery applicable after any cycle that includes turinabol
- When to Start PCT — clearance window guidance and how the compound’s 16-hour half-life affects PCT timing when stacked with a longer injectable
- Bulking vs Cutting Steroids — where non-aromatizing orals fit within the broader compound selection framework
For Educational Purposes Only
This guide discusses turinabol (4-chlorodehydromethyltestosterone) for educational and harm-reduction purposes. It does not constitute medical advice and is not a substitute for consultation with a qualified physician. Anabolic-androgenic steroids are controlled substances in many jurisdictions. All content is intended for informational purposes only.
MuscleScience.org does not sell any compounds, medications, or supplements. All author names are pseudonyms. Author photographs are stylized portraits, not images of real individuals. See our About page and Disclaimer for full editorial disclosure.
